Abstract
Ischemia/reperfusion (I/R) injury triggers cardiac dysfunctions via creating reactive oxygen species (ROS). Because xanthine oxidase (XO) is one of the major enzymes that generate ROS, inhibition of XO is expected to suppress ROS-induced I/R injury. However, it remains unclear whether XO inhibition really yields cardioprotection during I/R. The protective effects of the XO inhibitors, topiroxostat and allopurinol, on cardiac I/R injury were evaluated.Methods and Results:Using isolated rat hearts, ventricular functions, occurrence of arrhythmias, XO activities and thiobarbituric acid reactive substances (TBARS) productions and myocardial levels of adenine nucleotides before and after I/R, and cardiomyocyte death markers during reperfusion, were evaluated. Topiroxostat prevented left ventricular dysfunctions and facilitated recovery from arrhythmias during I/R. Allopurinol and the antioxidant, N-acetylcysteine (NAC), exhibited similar effects at higher concentrations. Topiroxostat inhibited myocardial XO activities and TBARS productions after I/R. I/R decreased myocardial levels of ATP, ADP and AMP, but increased that of xanthine. While topiroxostat, allopurinol or NAC did not change myocardial levels of ATP, ADP or AMP after I/R...Continue Reading
References
Jan 1, 1991·American Heart Journal·W D JohnsonS F Saedi
Jan 1, 1990·Annual Review of Physiology·M Tani
Jan 17, 1985·The New England Journal of Medicine·J M McCord
Jan 1, 1988·The Journal of Clinical Investigation·R D LasleyR M Mentzer
Nov 1, 1986·Circulation·C E MurryK A Reimer
Jun 1, 1984·Journal of Molecular and Cellular Cardiology·A S Manning, D J Hearse
Nov 1, 1982·Canadian Journal of Physiology and Pharmacology·J M McCord, R S Roy
Oct 1, 1984·Circulation Research·A S ManningD J Hearse
Aug 11, 1995·The Journal of Biological Chemistry·Y Xia, J L Zweier
Feb 1, 1994·Biochemical Medicine and Metabolic Biology·O I PisarenkoV I Kapelko
Jan 1, 1993·Free Radical Research Communications·S MalkielM Chevion
Nov 1, 1995·The Annals of Thoracic Surgery·S W MacGowanA E Wood
Dec 22, 1995·The Journal of Biological Chemistry·V J Thannickal, B L Fanburg
Apr 12, 1996·The Journal of Biological Chemistry·K D GarlidP A Schindler
Mar 1, 1995·Free Radical Biology & Medicine·C S YangJ S Kuo
Aug 26, 1998·Life Sciences·T AraiK Mori
Aug 29, 1998·Circulation Research·N G PérezE Marbán
Feb 23, 1999·Circulation·J NishizawaK Nagata
Mar 17, 1999·Diabetes·M ShimoyamaI Hisatome
May 3, 2001·Biochemistry. Biokhimii︠a︡·S Y KhatibF El-Migdadi
Aug 11, 2001·British Journal of Pharmacology·Y FuruseI Hisatome
Aug 27, 2003·Circulation Journal : Official Journal of the Japanese Circulation Society·Yoshiharu KinugasaChiaki Shigemasa
Mar 2, 2006·Pharmacological Reviews·Pál PacherCsaba Szabó
Jan 22, 2009·British Journal of Pharmacology·A TampoW M Kwok
Oct 19, 2010·The Journal of Pharmacology and Experimental Therapeutics·Koji MatsumotoTakeshi Nishino
Aug 9, 2011·Journal of Cardiovascular Pharmacology and Therapeutics·Roberta A Gottlieb
Apr 2, 2013·Archives of Toxicology·Krishnendu SinhaParames C Sil
Nov 12, 2013·Journal of Clinical Pharmacology·Atsushi SugiyamaYuji Kumagai
Nov 11, 2016·Clinical Rheumatology·Tatsuo HosoyaTetsuo Ohashi
Citations
Sep 27, 2019·The Journal of Clinical Hypertension·Shingo HigaKazuomi Kario
May 15, 2020·Journal of Clinical Pharmacy and Therapeutics·Shan-Shan SunJian-Yang Lin
Aug 28, 2020·Molecular and Cellular Biochemistry·Muhammad Afzal
Jun 30, 2019·Chinese Journal of Integrative Medicine·Da-Wei SunXin Qi
Jan 17, 2020·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hiroyuki MinatoYoshimi Inagaki
Jun 27, 2020·Zeitschrift Für Naturforschung. C, a Journal of Biosciences·Haiying FuMayu Huang
Jan 21, 2021·Free Radical Biology & Medicine·Yoshiro TanakaMichihiro Yoshimura
Jul 14, 2021·Diabetes & Metabolic Syndrome·Shingo Watanabe, Michio Usui
Oct 14, 2021·Clinical Rheumatology·Shunichiro TsukamotoKouichi Tamura